TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections

  • Biochimie. 2017 Nov;142:1-10. doi: 10.1016/j.biochi.2017.07.016.
Li Wen Shen  1 ,  Hui Juan Mao  1 ,  Yan Ling Wu  2 ,  Yoshimasa Tanaka  3 ,  Wen Zhang  4
Affiliations
  • 1. Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou, 310014, China.
  • 2. Lab of Molecular Immunology, Virus Inspection Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China. Electronic address: [email protected].
  • 3. Center for Innovation in Immunoregulative Technology and Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto, 606-8501, Japan.
  • 4. Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou, 310014, China. Electronic address: [email protected].
PMID: 28778717 DOI: 10.1016/j.biochi.2017.07.016
Abstract

Influenza Virus and coronavirus epidemics or pandemics have occurred in succession worldwide throughout the early 21st century. These epidemics or pandemics pose a major threat to human health. Here, we outline a critical role of the host cell protease TMPRSS2 in Influenza Virus and coronavirus infections and highlight an Antiviral therapeutic strategy targeting TMPRSS2.

Keywords
Coronavirus; Influenza virus; TMPRSS2; Therapeutics.
Products